
“The acquisition of the Taizihu Group will enable us to better provide products to the thriving global market for deep processed health food and drinks,” remarked Jianming Hao, the Chief Executive Officer and Chairman of Deyu. “The Taizihu Group has a well-developed product line consisting of over 100 types of foods and beverages, such as grain drinks, soybean products, and fruit vinegars and juices. In particular, its LongQuan Villa brand of fruit beverages and its Huichun brand of soybean products are well-recognized names among consumers in China. By leveraging the Taizihu Group’s product lines, we are looking to capture a more substantial share of the emerging worldwide market for deep processed health food and drinks while minimizing our risks in developing and introducing new products, establishing brands, cultivating markets and making products profitable.”
As a result of the acquisition, Deyu has integrated its sales network of over 16,000 retail stores with the Taizihu Group’s sales channels, which consist of 100 distributors in more than 10 provinces in China and export channels in Europe, USA, Japan and other countries. Accordingly, Deyu is confident that the acquisition of the Taizihu Group will help drive Deyu’s regional and global sales of its deep processed foods and drinks and packaged and unpackaged simple processed grain products.
Mr. Hao added, “In acquiring the Taizihu Group, which has products yielding high profit margins, advanced technologies, a management team with ample experience in the deep-processed food industry and a large manufacturing base of over a million square feet close to a key transport hub in Shanxi Province, we believe that we will be in a much better position to continue to grow our business and increase returns for our investors. All of us at Deyu are very excited about this acquisition as we believe that it presents us with a tremendous opportunity to expand our operations considerably.”
Deyu Agriculture (DEYU) Stock Quote and News:
Disclaimer: Neither http://www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has received no compensation for this article from and owns no shares of the aforementioned company(ies). Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/about-2/disclaimer.









According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the
0 comments
Add your comment
Commenting is allowed only for registered users.